Source:http://linkedlifedata.com/resource/pubmed/id/17922077
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-4-22
|
| pubmed:abstractText |
The dipeptide J1 acts as a prodrug of melphalan with a significant increased potency in vitro resulting from activation by cellular aminopeptidases. The current study was performed to evaluate the ex vivo profile of J1 using 176 primary tumor cell cultures from patients. In addition, the activity of J1 in combination with eight standard drugs, representing different mechanistic classes, was studied in nine different human tumor cell lines of different histopathological origin.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0167-6997
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
195-204
|
| pubmed:meshHeading |
pubmed-meshheading:17922077-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17922077-Cell Line, Tumor,
pubmed-meshheading:17922077-Dipeptides,
pubmed-meshheading:17922077-Drug Screening Assays, Antitumor,
pubmed-meshheading:17922077-Drug Synergism,
pubmed-meshheading:17922077-Fluorometry,
pubmed-meshheading:17922077-Humans,
pubmed-meshheading:17922077-Melphalan,
pubmed-meshheading:17922077-Neoplasms,
pubmed-meshheading:17922077-Prodrugs
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
|
| pubmed:affiliation |
Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Entrance 61, 4th floor, 75185 Uppsala, Sweden. Malin.Wickstrom@medsci.uu.se
|
| pubmed:publicationType |
Journal Article
|